EP1144997A3 - Methods and compounds for modulating nuclear receptor activity - Google Patents

Methods and compounds for modulating nuclear receptor activity

Info

Publication number
EP1144997A3
EP1144997A3 EP99916206A EP99916206A EP1144997A3 EP 1144997 A3 EP1144997 A3 EP 1144997A3 EP 99916206 A EP99916206 A EP 99916206A EP 99916206 A EP99916206 A EP 99916206A EP 1144997 A3 EP1144997 A3 EP 1144997A3
Authority
EP
European Patent Office
Prior art keywords
compounds
methods
receptor activity
nuclear receptor
modulating nuclear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99916206A
Other languages
German (de)
French (fr)
Other versions
EP1144997A2 (en
Inventor
Andrew Shiau
Peter J. Kushner
David A. Agard
Geoffrey L. Greene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Arch Development Corp
Original Assignee
University of California
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Arch Development Corp filed Critical University of California
Publication of EP1144997A2 publication Critical patent/EP1144997A2/en
Publication of EP1144997A3 publication Critical patent/EP1144997A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/20Screening for compounds of potential therapeutic value cell-free systems
EP99916206A 1998-03-30 1999-03-30 Methods and compounds for modulating nuclear receptor activity Withdrawn EP1144997A3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7995698P 1998-03-30 1998-03-30
US79956P 1998-03-30
US11301498P 1998-12-16 1998-12-16
US11314698P 1998-12-16 1998-12-16
US113014P 1998-12-16
US113146P 1998-12-16
PCT/US1999/006937 WO1999050658A2 (en) 1998-03-30 1999-03-30 Methods and compounds for modulating nuclear receptor activity

Publications (2)

Publication Number Publication Date
EP1144997A2 EP1144997A2 (en) 2001-10-17
EP1144997A3 true EP1144997A3 (en) 2002-08-28

Family

ID=27373576

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99916206A Withdrawn EP1144997A3 (en) 1998-03-30 1999-03-30 Methods and compounds for modulating nuclear receptor activity

Country Status (6)

Country Link
EP (1) EP1144997A3 (en)
JP (1) JP2002516983A (en)
KR (1) KR20010042373A (en)
AU (1) AU3457199A (en)
CA (1) CA2324060A1 (en)
WO (1) WO1999050658A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323575A1 (en) * 1998-03-30 1999-11-25 Regents Of The University Of California Methods and compounds for modulating nuclear receptor coactivator binding
WO2000052050A2 (en) * 1999-03-01 2000-09-08 Karo Bio Ab Homology models of the glucocorticoid receptor
WO2001027622A1 (en) 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
FR2801311B1 (en) * 1999-11-22 2005-08-26 Centre Nat Rech Scient POLYPEPTIDES DERIVED FROM THE NUCLEAR RECEPTOR OF VITAMIN D, AND USES THEREOF IN PARTICULAR IN THE SCREENING OF ANALOGUES OF VITAMIN D
EP1297175A4 (en) * 2000-06-30 2005-02-02 Univ California Methods and compounds for modulating nuclear receptor coactivator binding
DE10036461A1 (en) * 2000-07-25 2002-02-07 Bayer Ag Ligand binding domain of the Ultraspiracle (USP) protein
JP4593754B2 (en) * 2000-10-13 2010-12-08 一般財団法人 化学物質評価研究機構 Method for determining 50% inhibitory concentration of chemical substances
JP2002296282A (en) * 2001-04-02 2002-10-09 Enbiotec Laboratories:Kk Method of detecting exogeneous endocrine disturbing substance
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
GB0209507D0 (en) * 2002-04-25 2002-06-05 Karobio Ab Nuclear receptor structure
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
WO2005022436A1 (en) * 2003-08-29 2005-03-10 National Institute Of Advanced Industrial Science And Technology Protein structure three-dimensional display system for indication of protein function manifestation mechanism
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
EP1680447A2 (en) * 2003-10-24 2006-07-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Orthogonal gene switches
KR20110110052A (en) * 2010-03-31 2011-10-06 (주)아모레퍼시픽 Composition for beauty of skin containing coumestrol or soy bean extract with coumestrol
WO2011156518A2 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
BR112014014124A2 (en) 2011-12-14 2017-08-22 Seragon Pharmaceutical Inc FLUORINATED ESTROGEN RECEPTOR MODULATORS AND THEIR USES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
ATE148889T1 (en) * 1991-09-18 1997-02-15 Affymax Tech Nv METHOD FOR SYNTHESIS OF VARIOUS COLLECTIONS OF OLIGOMERS
JP3394777B2 (en) * 1993-05-27 2003-04-07 セレクタイド コーポレーション Topologically separated, encoded solid-phase library
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
JP2000502086A (en) * 1995-12-13 2000-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Nuclear receptor ligands and ligand binding domains

Also Published As

Publication number Publication date
EP1144997A2 (en) 2001-10-17
WO1999050658A2 (en) 1999-10-07
WO1999050658A3 (en) 2001-08-16
KR20010042373A (en) 2001-05-25
AU3457199A (en) 1999-10-18
JP2002516983A (en) 2002-06-11
CA2324060A1 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
GB2327787B (en) Methods and systems for knowledge management
AU9790198A (en) Compounds and methods
AU6347498A (en) Catheter system for emboli containment
AU1556301A (en) Data distribution system and recorder for use therein
AU9298098A (en) Amino-substituted compounds, methods, and compositions for inhibiting parp activity
AU1651701A (en) Data distribution system and recorder for use therein
EP1144997A3 (en) Methods and compounds for modulating nuclear receptor activity
AU9298198A (en) Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU7819598A (en) Soil testing assemblies
AU7134198A (en) Improved cell design for a trawl system and methods
AU3544899A (en) Multiple reactor containment building
AU2032397A (en) Biodecontamination reactor
AU5279798A (en) Urine bag assemblies
AU2668699A (en) Methods and compositions for modulating leptin activity
AU4109097A (en) Interaction area for data representation
AU1038599A (en) Method for secure storage management
HK1028665A1 (en) Apparatus for passbook management
AUPP696798A0 (en) Improved reactor
EP0882802A4 (en) Method for assaying telomerase activity
AU1033397A (en) Biogas reactor
AU9167698A (en) Mini-stencil and device for using same
AU3852997A (en) Phenoxypropanolamines having beta3-adrenergic antagonist activity
AU6351298A (en) Containment system
AU9370998A (en) Transformer/reactor
AU8115298A (en) Catalytic reactor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001024

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

XX Miscellaneous

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20050209

17Q First examination report despatched

Effective date: 20050209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061003